Abstract

A REVIEW ON ESTIMATION OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE IN BULK AND IN PHARMACEUTICAL DOSAGE FORM

Ankita V. Deodhe*, Dr. N. S. Dighe, Prof. S. D. Magar, Prof. G. S. Shinde and Jyoti J. Vikhe

Abstract

Antiretroviral therapy has ability to reduce HIV infection by increasing CD4+ (cluster of differentiation) count. Emtricitabine belong to class nucleoside reverse transcriptase inhibitor and Tenofovir Disoproxil fumarate belong to nucleotide reverse transcriptase inhibitor but same use (HIV1 and hepatitis B) and same route of transmission. The literature has revealed that number of method have been published for estimation of Emtricitabine and Tenofovir Disoproxil fumarate like RP-HPLC, Spectrophotometric (UV), UPLC, etc. These methods were reported for analysis. The review gives information of Development and validation of Emtricitabine and Tenofovir Disoproxil fumarate in bulk and pharmaceutical dosage form and validation as per ICH Guideline. This is a Fixed drug combination available in this era. These drugs are also compatible with other antiretroviral drugs having greater or equal potency and less side effect than traditional antiretroviral drugs.

Keywords: Emtricitabine, Tenofovir Disoproxil fumarate, Analytical methods, Antiretroviral.